Description Results NMA

death, MI, recurrent ischaemia, use of Gp2b3a inhibitor 0,58 [0,34; 0,99]

death, MI 0,56 [0,30; 1,04]

TIMI major or minor bleeding not related to CABG 1,26 [0,63; 2,52]

Thrombotic complication during PCI 1,44 [0,59; 3,52]

otamixaban 5 doses (0·08 mg/kg bolus followed by 0.035, 0.070, 0.105, 0.140, 0.175 mg/kg/h) (n=2792)

vs.

Heparin+eptifibatide (n=449)

6 arms phase 2: otamixaban 5 doses (0·08 mg/kg bolus followed by 0.035, 0.070, 0.105, 0.140, 0.175 mg/kg/h) and unfractionated heparin + eptifi batide

double blind

Parallel groups

Sample size: 2792/449

Primary endpoint: death, MI, recurrent ischaemia, use of Gp2b3a

FU duration: 7 days

dose finding study